痞子英雄

Arijit Singh Brings Heart and Harmony to His New Romantic Single Fitratein_我的网站

一 |     Arijit Singh returns with Fitratein. It is a soul stirring romantic track that captures the tenderness of love, longing, and quiet hope. Released today on Times Music, the song showcases Arijit in timeless form. He delivers a performance filled with warmth and emotional purity. Composed by Ronak Phukan and written by Syed Amir Hussain and Soham Majumdar, Fitratein carries a soft and lingering charm that gently pulls listeners into its world.          Bringing the story to life on screen are the magnetic Sanam Johar and the beautiful Kanikka Kapur. Sanam’s expressive presence and effortless sincerity blend beautifully with Kanikka’s graceful screen appeal and natural elegance. Together, they create a refreshing romantic energy that anchors the narrative of rekindled love, making the song a fitting addition to the festive season.Sanam Johar said, “Being part of an Arijit Singh song is always a huge moment. His voice transforms even a simple emotion into something unforgettable. Fitratein is built on pure romance, and having Arijit sing it makes it even more magical. I am glad to collaborate with Times Music again on something this special.”Kanikka Kapur said, “The first time I heard Fitratein, I knew Arijit Singh had created something beautiful again. His voice adds a soft intensity that lifts the whole story. Shooting this song felt like living a warm memory, and I hope people fall in love with it just as deeply.”Mandar Thakur, CEO, Times Music, said, “Every Arijit Singh track is a cultural moment and Fitratein is the best of the season. There is no better way to feel the magic of the festival season than with this song.”Watch it on YouTube:                                         Fitratein is now available on Times Music’s YouTube channel and on all leading music streaming platforms.Also Read: Kesariya Team Reunites for Hrithik Roshan & Kiara Advani’s Romantic War 2 Song。    (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

Current article:http://q7v72h.longdachemakuanshan.pics/list_069raqw/vz45f.html

Published on:19:49:33